KR102012222B1 - 무기질코르티코이드 수용체 조절제로서의 벤족사지논 아미드 - Google Patents

무기질코르티코이드 수용체 조절제로서의 벤족사지논 아미드 Download PDF

Info

Publication number
KR102012222B1
KR102012222B1 KR1020177002518A KR20177002518A KR102012222B1 KR 102012222 B1 KR102012222 B1 KR 102012222B1 KR 1020177002518 A KR1020177002518 A KR 1020177002518A KR 20177002518 A KR20177002518 A KR 20177002518A KR 102012222 B1 KR102012222 B1 KR 102012222B1
Authority
KR
South Korea
Prior art keywords
dihydro
benzoxazin
oxo
mmol
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177002518A
Other languages
English (en)
Korean (ko)
Other versions
KR20170021883A (ko
Inventor
개빈 오마호니
마이클 코센얀스
칼 에드만
요한 카야누스
칼 안드레스 호그네르
필립 코른왈
앤드류 터너
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20170021883A publication Critical patent/KR20170021883A/ko
Application granted granted Critical
Publication of KR102012222B1 publication Critical patent/KR102012222B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020177002518A 2014-06-30 2015-06-26 무기질코르티코이드 수용체 조절제로서의 벤족사지논 아미드 Active KR102012222B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30
US62/018,790 2014-06-30
PCT/GB2015/051860 WO2016001631A1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators

Publications (2)

Publication Number Publication Date
KR20170021883A KR20170021883A (ko) 2017-02-28
KR102012222B1 true KR102012222B1 (ko) 2019-10-21

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177002518A Active KR102012222B1 (ko) 2014-06-30 2015-06-26 무기질코르티코이드 수용체 조절제로서의 벤족사지논 아미드

Country Status (26)

Country Link
US (2) US10017502B2 (enExample)
EP (1) EP3160948B1 (enExample)
JP (1) JP6368383B2 (enExample)
KR (1) KR102012222B1 (enExample)
CN (1) CN106536491B (enExample)
AR (1) AR101036A1 (enExample)
AU (1) AU2015282450C1 (enExample)
CA (1) CA2953655C (enExample)
CY (1) CY1121596T1 (enExample)
DK (1) DK3160948T3 (enExample)
EA (1) EA029518B1 (enExample)
ES (1) ES2707726T3 (enExample)
HR (1) HRP20190147T1 (enExample)
HU (1) HUE042370T2 (enExample)
LT (1) LT3160948T (enExample)
ME (1) ME03316B (enExample)
MX (1) MX367404B (enExample)
PL (1) PL3160948T3 (enExample)
PT (1) PT3160948T (enExample)
RS (1) RS58274B1 (enExample)
SI (1) SI3160948T1 (enExample)
SM (1) SMT201900039T1 (enExample)
TR (1) TR201900659T4 (enExample)
TW (1) TWI677498B (enExample)
UY (1) UY36195A (enExample)
WO (1) WO2016001631A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03316B (me) * 2014-06-30 2019-10-20 Astrazeneca Ab Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora
JOP20210009A1 (ar) 2018-07-19 2021-01-12 Astrazeneca Ab طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
BR112020008705A2 (pt) * 2019-08-30 2022-03-22 Astrazeneca Ab Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina
JP2023536009A (ja) 2020-07-27 2023-08-23 アストラゼネカ・アクチエボラーグ ダパグリフロジンによる慢性腎疾患の処置方法
BR112023025793A2 (pt) * 2021-06-15 2024-02-27 Chia Tai Tianqing Pharmaceutical Group Co Ltd Composto de fórmula (ii), um estereoisômero deste ou um sal farmaceuticamente aceitável deste, composição farmacêutica e uso do composto
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
US20250381145A1 (en) 2022-09-01 2025-12-18 Astrazeneca Ab Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases
WO2024125591A1 (zh) * 2022-12-15 2024-06-20 正大天晴药业集团股份有限公司 苯并恶嗪酮类化合物的结晶及其制备
AU2024387082A1 (en) 2023-11-21 2026-06-04 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085868A1 (en) * 2001-04-23 2002-10-31 Astrazeneca Ab Benzoxazinone derivatives for use in the treatment of angiogenesis
WO2004056820A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
CN101018552A (zh) * 2004-07-14 2007-08-15 利亘制药公司 细胞内受体调节剂化合物和方法
RU2007107177A (ru) * 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
TW200732331A (en) 2005-12-28 2007-09-01 Takeda Pharmaceuticals Co Fused heterocyclic compound and use thereof
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
ES2375877T3 (es) 2006-10-31 2012-03-07 Pfizer Products Inc. Compuestos de pirazolina como antagonistas de receptores de mineralocorticoides.
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
US8063090B2 (en) 2007-03-23 2011-11-22 Merck Sharp & Dohme Corp. Mineralocorticoid receptor modulators
TWI444185B (zh) 2007-04-09 2014-07-11 Daiichi Sankyo Co Ltd 吡咯衍生物之阻轉異構物
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
JP2011524896A (ja) * 2008-06-18 2011-09-08 アストラゼネカ・アクチエボラーグ 呼吸器障害の処置用のベータ２−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
CA2756250A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
WO2011141846A2 (en) 2010-05-11 2011-11-17 Koninklijke Philips Electronics N.V. Lighting module
EP2569310A1 (en) 2010-05-11 2013-03-20 Pfizer Inc Morpholine compounds as mineralocorticoid receptor antagonists
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
EP2638012A1 (en) 2010-11-10 2013-09-18 Boehringer Ingelheim International GmbH Pyridyl ureas as mineralocorticoid receptor antagonists
ME03316B (me) * 2014-06-30 2019-10-20 Astrazeneca Ab Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry, 21(19), 5983-5994, 2013.

Also Published As

Publication number Publication date
HUE042370T2 (hu) 2019-06-28
ES2707726T3 (es) 2019-04-04
SI3160948T1 (sl) 2020-06-30
AU2015282450B2 (en) 2018-05-10
MX2017000183A (es) 2017-04-25
JP2017522300A (ja) 2017-08-10
LT3160948T (lt) 2019-02-11
TWI677498B (zh) 2019-11-21
CN106536491B (zh) 2018-12-18
JP6368383B2 (ja) 2018-08-01
CN106536491A (zh) 2017-03-22
RS58274B1 (sr) 2019-03-29
US20150376170A1 (en) 2015-12-31
ME03316B (me) 2019-10-20
MX367404B (es) 2019-08-20
WO2016001631A1 (en) 2016-01-07
KR20170021883A (ko) 2017-02-28
US9394291B2 (en) 2016-07-19
EA029518B1 (ru) 2018-04-30
EP3160948B1 (en) 2018-10-24
CY1121596T1 (el) 2020-05-29
AR101036A1 (es) 2016-11-16
CA2953655A1 (en) 2016-01-07
US20170217945A1 (en) 2017-08-03
AU2015282450C1 (en) 2018-09-20
AU2015282450A1 (en) 2017-02-02
PT3160948T (pt) 2019-02-01
PL3160948T3 (pl) 2019-04-30
EA201790046A1 (ru) 2017-08-31
UY36195A (es) 2016-01-08
EP3160948A1 (en) 2017-05-03
US10017502B2 (en) 2018-07-10
TR201900659T4 (tr) 2019-02-21
SMT201900039T1 (it) 2019-02-28
CA2953655C (en) 2020-05-12
DK3160948T3 (en) 2019-02-18
TW201613909A (en) 2016-04-16
HRP20190147T1 (hr) 2019-03-22

Similar Documents

Publication Publication Date Title
JP6368383B2 (ja) 鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド
JP5564036B2 (ja) ヒストン脱アセチル化酵素阻害薬としてのスピロ環誘導体
JP6211530B2 (ja) 含窒素複素環化合物
JP2022503942A (ja) イソインドリン化合物、その調製方法、医薬組成物および使用
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
EP3404032B1 (en) Process for making benzoxazepin compounds
CA2993312A1 (en) 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
CZ283680B6 (cs) Nové azaheterocyklylmethyl-chromany
JP7579249B2 (ja) ヒストンアセチラーゼｐ３００阻害剤及びその用途
CN105073724A (zh) 作为钾离子通道抑制剂的2,3-二氮杂萘类化合物
EP2501233B1 (en) Quinazoline compounds
EP3373931A1 (en) Heterocyclic compounds for the treatment of disease
AU2019230859B2 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
HK1237338B (en) Benzoxazinone amides as mineralocorticoid receptor modulators
HK1237338A1 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
WO2026099404A1 (en) Sulfonylurea derivatives and their use for the treatment of cancer
황궈청 Part I. Synthesis and antitumor activities of neorautenol and shinpterocarpin analogs Part II. Discovery of N-(1, 4-benzoxazin-3-one) urea analogs as mode-selective TRPV1 antagonists
WO2026098529A1 (en) Kinesin kif18a inhibitors and use thereof
HK40075698B (en) 1,3,4 oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
HK1165791A1 (en) Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
HK1165791B (en) Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
CN102796075A (zh) 苯并环庚烯类衍生物、其制备方法及医药用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20220630

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8